CD47 and non-small cell lung carcinoma: Recent clinical trials have indicated that inhibition of this pathway with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies [20, 21].